Dublin, Dec. 15, 2021 (GLOBE NEWSWIRE) -- The "Methicillin-Resistant Staphylococcus Aureus Drugs Market Research Report by Drug Class, MOA, Drug Origin, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Methicillin-Resistant Staphylococcus Aureus Drugs Market size was estimated at USD 1,542.93 million in 2020, is expected to reach USD 1,623.64 million in 2021, and projected to grow at a CAGR of 5.56% reaching USD 2,135.87 million by 2026.
Market Statistics
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Market Segmentation & Coverage
This research report categorizes the Methicillin-Resistant Staphylococcus Aureus Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Drug Class, the market was studied across Cephalosporin, Folate Antagonist, Lipoglycopeptide, Lipopeptides, Oxazolidinone, and Tetracycline.
- Based on MOA, the market was studied across Bactericidal Drugs and Bacteriostatic.
- Based on Drug Origin, the market was studied across Semisynthetic and Synthetic Drugs.
- Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Competitive Strategic Window
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Methicillin-Resistant Staphylococcus Aureus Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market, including Allergan, AmpliPhi Biosciences Corporation, Basilea Pharmaceutica, Baxter International, Debiopharm Group, KYORIN Pharmaceutical Co. Ltd., Melinta Therapeutics, Merck, Pfizer, and Theravance Biopharma.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?
6. What is the market share of the leading vendors in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increased prevalence of global infections and demand for novel therapies
5.2.2. Growing awareness about a bacterial infection
5.2.3. Increase in immuno-compromised population
5.3. Restraints
5.3.1. Lack of systematic surveillance for MRSA infection in developing countries
5.3.2. High cost of novel MRSA drugs and hospital readmissions reduction program
5.4. Opportunities
5.4.1. Rise in research activities to develop novel MRSA drugs by key players and support by government initiatives
5.4.2. Rising product launches and approvals
5.4.3. Unmet need for the MRSA infection
5.5. Challenges
5.5.1. Introduction of low-cost generic drugs
6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class
6.1. Introduction
6.2. Cephalosporin
6.3. Folate Antagonist
6.4. Lipoglycopeptide
6.5. Lipopeptides
6.6. Oxazolidinone
6.7. Tetracycline
7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by MOA
7.1. Introduction
7.2. Bactericidal Drugs
7.3. Bacteriostatic
8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Origin
8.1. Introduction
8.2. Semisynthetic
8.3. Synthetic Drugs
9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, by Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Allergan
13.2. AmpliPhi Biosciences Corporation
13.3. Basilea Pharmaceutica
13.4. Baxter International
13.5. Debiopharm Group
13.6. KYORIN Pharmaceutical Co. Ltd.
13.7. Melinta Therapeutics
13.8. Merck
13.9. Pfizer
13.10. Theravance Biopharma
14. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/u0e8b8
